Standout Papers

Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis... 1999 2026 2008 2017 2.9k
  1. Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis (2005)
    Paul Rutgeerts, William J. Sandborn et al. New England Journal of Medicine
  2. Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis (2013)
    Brian G. Feagan, Paul Rutgeerts et al. New England Journal of Medicine
  3. Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment (2012)
    Xochitl C. Morgan, Timothy L. Tickle et al. Genome biology
  4. Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease (2013)
    William J. Sandborn, Brian G. Feagan et al. New England Journal of Medicine
  5. Infliximab for the Treatment of Fistulas in Patients with Crohn's Disease (1999)
    Daniel H. Present, Paul Rutgeerts et al. New England Journal of Medicine
  6. Infliximab Maintenance Therapy for Fistulizing Crohn's Disease (2004)
    Bruce E. Sands, Frank Anderson et al. New England Journal of Medicine
  7. STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD (2021)
    Dan Turner, Amanda Ricciuto et al. Gastroenterology
  8. Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis (2017)
    William J. Sandborn, Chinyu Su et al. New England Journal of Medicine
  9. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial (2012)
    Wolfgang Hueber, Bruce E. Sands et al. Gut
  10. ACG Clinical Guideline: Management of Crohn's Disease in Adults (2018)
    Gary R. Lichtenstein, Edward V. Loftus et al. The American Journal of Gastroenterology
  11. Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease (2012)
    William J. Sandborn, Christopher Gasink et al. New England Journal of Medicine
  12. Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis (2019)
    Bruce E. Sands, William J. Sandborn et al. New England Journal of Medicine
  13. Early Mucosal Healing With Infliximab Is Associated With Improved Long-term Clinical Outcomes in Ulcerative Colitis (2011)
    Jean‐Frédéric Colombel, Paul Rutgeerts et al. Gastroenterology
  14. The safety of vedolizumab for ulcerative colitis and Crohn's disease (2016)
    Jean‐Frédéric Colombel, Bruce E. Sands et al. Gut
  15. Effects of Vedolizumab Induction Therapy for Patients With Crohn’s Disease in Whom Tumor Necrosis Factor Antagonist Treatment Failed (2014)
    Bruce E. Sands, Brian G. Feagan et al. Gastroenterology
  16. Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis (2019)
    Bruce E. Sands, Laurent Peyrin‐Biroulet et al. New England Journal of Medicine
  17. Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS) (2011)
    Simon Travis, Dan Schnell et al. Gut
  18. Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials (2017)
    Julián Panés, William J. Sandborn et al. Gut
  19. Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies (2023)
    William J. Sandborn, Séverine Vermeire et al. The Lancet
  20. Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis (2023)
    Geert D’Haens, Marla C. Dubinsky et al. New England Journal of Medicine
  21. Guselkumab for the Treatment of Crohn’s Disease: Induction Results From the Phase 2 GALAXI-1 Study (2022)
    William J. Sandborn, Geert D’Haens et al. Gastroenterology

Immediate Impact

4 by Nobel laureates 13 from Science/Nature 192 standout
Sub-graph 1 of 13

Citing Papers

Crohn's disease
2024 Standout
Ulcerative colitis
2023 Standout
303 intermediate papers

Works of Bruce E. Sands being referenced

STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
2021 Standout
Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis
2019 Standout
and 127 more

Author Peers

Author Last Decade Papers Cites
Bruce E. Sands 27560 20316 10502 579 38.2k
Remo Panaccione 25603 18908 9789 684 35.4k
Gert Van Assche 26295 20158 10425 445 35.8k
Geert D’Haens 30399 23520 11890 897 41.6k
Laurent Peyrin‐Biroulet 32828 24374 12865 1.1k 47.8k
Stephan R. Targan 17995 12274 5869 428 30.4k
Brian G. Feagan 40888 31094 14136 747 52.5k
Silvio Danese 28863 20178 12757 1.3k 48.6k
Stefan Schreiber 25944 17883 10133 870 50.1k
Edward V. Loftus 25630 21033 13328 755 36.2k
Jean‐Frédéric Colombel 41043 31226 15887 711 57.3k

All Works

Loading papers...

Rankless by CCL
2026